In the Phase II study of the product candidate TB-402 for the prevention of thrombosis, the treatment of patients in the third and final 100 patient cohort was started in September.
In the Phase II study of the product candidate TB-402 for the prevention of thrombosis, the treatment of patients in the third and final 100 patient cohort was started in September.
